ArticleJournal of Brown hospital medicine2026
Thrombotic Microangiopathy And Hypertensive Emergency After Cocaine Use: A Case Report.
Article in Journal of Brown hospital medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A patient in her early 60s presented with hypertensive emergency, microangiopathic hemolytic anemia, thrombocytopenia, and non-oliguric acute kidney injury (AKI) after recent cocaine use. The evaluation demonstrated schistocytes, a Coombs-negative hemolysis pattern, and preserved ADAMTS13 activity, making TTP unlikely. Kidney biopsy confirmed acute thrombotic microangiopathy (TMA) and excluded alternative intrinsic renal pathologies. Autoimmune and infectious workup was unrevealing. Although cocaine exposure temporally preceded presentation, malignant hypertension and complement activation may represent overlapping and potentially synergistic mechanisms rather than a single unifying etiology. Blood pressure control improved hemodynamics, but kidney function continued to worsen, and soluble C5b-9 (sC5b-9) was elevated. Eculizumab was initiated empirically after appropriate vaccination due to persistent renal dysfunction despite blood pressure optimization, recognizing that sC5b-9 is not specific for atypical HUS and may be elevated in secondary TMAs. Renal function subsequently stabilized, and the patient remained dialysis-free at three-month follow-up.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.